From: A new prognostic histopathologic classification of nasopharyngeal carcinoma
Characteristic | Training cohort | Retrospective validation cohort | Prospective validation cohort |
---|---|---|---|
Total (cases) | 2716 | 1702 | 1613 |
Age (years) | |||
 Median (range) | 46 (10–86) | 47 (10–90) | 47 (11–83) |
Follow-up time (months) | |||
 Median (range) | 68 (1–120) | 68 (1–120) | 41 (1–91) |
Sex [cases (%)] | |||
 Female | 658 (24.2) | 501 (29.4) | 404 (25.1) |
 Male | 2058 (75.8) | 1201 (70.6) | 1209 (74.9) |
Clinical stage [cases (%)] | |||
 I | 75 (2.8) | 67 (4.0) | 35 (2.2) |
 II | 549 (20.2) | 388 (22.8) | 104 (6.5) |
 III | 1272 (46.8) | 695 (40.8) | 458 (28.4) |
 IV | 820 (30.2) | 552 (32.4) | 1016 (62.9) |
Therapeutic modality [cases (%)] | |||
 Radiotherapy alone | 1592 (58.6) | 928 (54.5) | 220 (13.6) |
 Radiochemotherapy | 1124 (41.4) | 774 (45.5) | 1393 (86.4) |
Proposed classification [cases (%)] | |||
 EC | 1520 (55.9) | 987 (58.0) | 1202 (74.5) |
 MSEC | 598 (22.0) | 420 (24.7) | 229 (14.2) |
 SC | 489 (18.0) | 198 (11.6) | 135 (8.4) |
 SCC | 109 (4.1) | 97 (5.7) | 47 (2.9) |
WHO classification [case (%)] | |||
 NKUC | 2261 (83.2) | 1425 (83.8) | 1185 (73.5) |
 NKDC | 409 (15.1) | 227 (13.3) | 414 (25.7) |
 KSCC | 46 (1.7) | 50 (2.9) | 14 (0.8) |
OS rate (%) | |||
 5-year (95% CI) | 68.7 (66.9–70.5) | 73.3 (71.1–75.4) | 83.5 (81.1–85.6) |